In This Article:
Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and expanding patient eligibility by reducing contraindications. “In addition to the established efficacy of Camzyos, these meaningful updates to the label reinforce the strong safety profile of the therapy. With robust clinical and real-world data and more than 15,000 patients prescribed Camzyos in the U.S., this medicine has redefined the treatment landscape for symptomatic obstructive HCM and can have a significant impact for patients living with the condition. Simplifying treatment by reducing the frequency of echo monitoring not only improves the patient experience, but will also save time for cardiologists, allowing them to treat more patients,” said Al Reba, senior vice president, Cardiovascular & Immunology Commercialization at Bristol Myers Squibb.
Stay Ahead of the Market:
-
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
-
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY: